ResMed's SWOT analysis: sleep tech giant faces GLP-1 drug challenge
ResMed Inc . (NYSE:RMD; ASX:RMD), a leading player in the sleep and respiratory care market, has demonstrated strong operational performance in recent quarters. However, the company faces potential ...
HME News4d
ResMed moves to address ‘educational gap’ on PAP devices, GLP-1s
In the wake of the U.S. Food and Drug Administration’s approval of Zepbound to treat moderate to severe obstructive sleep ...
Investor's Business Daily on MSN4d
ResMed Tumbles As Organic Sales Growth Steps Down. Will These 'Mega Trends' Save It?
ResMed stock tumbled Friday after organic sales growth slowed somewhat in the second fiscal quarter. But one analyst was upbeat.
The Financial Express28d
ResMed launches new device for patients of sleep apnea in India
ResMed on Tuesday announced that it has launched AirSense 11 in India. According to the company’s statement, it is the next-generation Continuous Positive Airway Pressure (CPAP) device designed ...
Morningstar5d
ResMed's Moat Is Underpinned by Switching Costs and Intangible Brand Assets
or CPAP, with another 34 million remaining undiagnosed. ResMed operates in over 140 countries with over 900 million people estimated to have sleep apnea globally, indicating the long runway for ...